Prof. Dr. Beat Thürlimann
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Colleoni M, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates A, Price K, Fey M, Collins J, Zahrieh D, Gelber R, Holmberg S, Mattsson J, Rudenstam C, Lindtner J, Erzen D, Snyder R, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. JCO 2005; 23:1390-400.
Mar 1, 2005Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Mar 1, 2005JCO 2005; 23:1390-400
Colleoni Marco, Thürlimann Beat, Crivellari Diana, Murray Elizabeth, Mendiola Caesar, Pagani Olivia, Castiglione-Gertsch Monica, Coates Alan S, Price Karen, Fey Martin F, Collins John, Zahrieh David, Gelber Richard D, Holmberg Stig B, Mattsson Jan E, Rudenstam Carl-Magnus, Lindtner Jurij, Erzen Darja, Snyder Raymond, Goldhirsch Aron
Current concepts of treatment strategies in advanced or recurrent ovarian cancer
Salzberg M, Thürlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68:293-8.
Jan 1, 2005Current concepts of treatment strategies in advanced or recurrent ovarian cancer
Jan 1, 2005Oncology 2005; 68:293-8
Salzberg Marc, Thürlimann Beat, Bonnefois Hervé, Fink Daniel, Rochlitz Christoph, von Moos Roger, Senn Hansjorg
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
Dec 1, 2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Dec 1, 2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.
Nov 29, 2004Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Nov 29, 2004BJC 2004; 91:1893-901
Bernhard J, Goldhirsch A, Price K N, Fey M F, Thürlimann Beat, Veronesi A, Crivellari D, Rudenstam C-M, Snyder R, Collins J, Perey L, Forbes J F, Murray E, Castiglione-Gertsch M, Gelber R D, Coates A S, Zahrieh D, Hürny C
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
Sep 1, 2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sep 1, 2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Berclaz G, Thürlimann B, Fey M, Mendiola C, Werner I, Simoncini E, Crivellari D, Gelber R, Goldhirsch A, Snyder R, Collins J, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam C, Holmberg S, Lindtner J, Erien D, International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004; 15:875-84.
Jun 1, 2004Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Jun 1, 2004Ann Oncol 2004; 15:875-84
Berclaz G, Thürlimann Beat, Fey M F, Mendiola C, Werner I Dudley, Simoncini E, Crivellari D, Gelber R D, Goldhirsch A, Snyder R, Collins J, Li S, Price K N, Coates A S, Castiglione-Gertsch M, Rudenstam C-M, Holmberg S B, Lindtner J, Erien D, International Breast Cancer Study Group
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.
Jun 1, 2004Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Jun 1, 2004Breast Cancer Res Treat 2004; 85:247-54
Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörger M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). Strahlenther Onkol 2004; 180 Suppl 1:89-108.
Jun 1, 2004Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Jun 1, 2004Strahlenther Onkol 2004; 180 Suppl 1:89-108
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A D, Morel Ph, Gertsch P, Gervaz P, Davis J B, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U M, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E S, Rutz H P, Lomax A J, Weber D C, Luthi F, Pasche P, Bentzen S M, Khalil A A, Dubois J B, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D O, Dische S, Cummings B J, Van den Bogaert W, Horiot J C, Saunders M I, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H J, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J F, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H P, Balmer A, Munier F, Jargy C, Dipasquale G, Born E J, Szczerba D, Hueber P, Hafner H P, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M-A, Krayenbühl J, Schoenmaker E, Norton I A, Baumert B G, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D B, Romieu G, Bodis St, Stahel R, Weder W, Jerman M, Schneiter D, Jörger Markus, Lardinois D, Taverna Ch, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R H, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum Wolfram, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D M, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A S, Behrensmeier F, Thürlimann Beat, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S B, Rudenstam C-M, Castiglione-Gertsch M, Price K N, Nasi M L, Bonetti M, Simoncini E, Fey M F, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R O, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A S, Gelber R D, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann Ch, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I F, Friedrich E E, Beer K T, Balmer Majno S, Hügli A, Gallino A, Juelke Peter D, Pajic B, Curschmann J, Bieri S, Luthi J C, Suleiman M, Bargetzi M, Notter M, Thum Peter, Resink Therese Josephine, Erne Paul, Jamshidi Peiman, Hafner Hans-Peter, Mach N
Re: Playing the old piano: another tune for endocrine therapy
Köberle D, Perey L, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK). Re: Playing the old piano: another tune for endocrine therapy. Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7.
Apr 7, 2004Re: Playing the old piano: another tune for endocrine therapy
Apr 7, 2004Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7
Köberle Dieter, Perey Lucien, Thürlimann Beat, Swiss Group for Clinical Cancer Research (SAKK)
Management of primary breast cancer: an update
Thürlimann B, Muller A, Senn H. Management of primary breast cancer: an update. Onkologie 2004; 27:175-9.
Apr 1, 2004Management of primary breast cancer: an update
Apr 1, 2004Onkologie 2004; 27:175-9
Thürlimann Beat, Muller A, Senn H-J
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
Senn H, Thürlimann B, Goldhirsch A, Wood W, Gelber R, Coates A. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast (Edinburgh, Scotland) 2003; 12:569-82.
Dec 1, 2003Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
Dec 1, 2003Breast (Edinburgh, Scotland) 2003; 12:569-82
Senn H-J, Thürlimann Beat, Goldhirsch A, Wood W C, Gelber R D, Coates A S
The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'
Senn H, Thürlimann B. The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'. Breast (Edinburgh, Scotland) 2003; 12:349-50.
Dec 1, 2003The importance of evidence-based international consensus in the primary treatment of breast cancer--a periodic 'must'
Dec 1, 2003Breast (Edinburgh, Scotland) 2003; 12:349-50
Senn Hans-Jörg, Thürlimann Beat
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7.
Nov 1, 2003Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
Nov 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:2310-7
Thürlimann Beat, Robertson J F R, Nabholtz J M, Buzdar A, Bonneterre J, Arimidex Study Group
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:3357-65.
Sep 1, 2003Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
Sep 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:3357-65
Goldhirsch Aron, Wood William C, Gelber Richard D, Coates Alan S, Thürlimann Beat, Senn Hans-Jörg
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Nabholtz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9.
Aug 1, 2003Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Aug 1, 2003European journal of cancer (Oxford, England : 1990) 2003; 39:1684-9
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J F R, Thürlimann Beat
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.
Aug 1, 2003Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Aug 1, 2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann Beat, Goldhirsch A, Brunner K W, Borner M M, Swiss Group for Clinical Cancer Research (SAKK)
Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study
von Moos R, Thürlimann B. Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study. Onkologie 2003; 26:128-32.
Apr 1, 2003Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study
Apr 1, 2003Onkologie 2003; 26:128-32
von Moos R, Thürlimann Beat
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13.
Apr 1, 2003Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Apr 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13
Wallgren A, Collins J, Coates A S, Price K, Forbes J F, Werner I D, Fey M, Thürlimann Beat, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Goldhirsch A, Gelber R D, Bonetti M, International Breast Cancer Study Group Trials I through VII
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
Aapro M, Thürlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7.
Feb 1, 2003A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
Feb 1, 2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:291-7
Aapro M S, Thürlimann Beat, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research
Anastrozole versus progestins/tamoxifen
Thürlimann B. Anastrozole versus progestins/tamoxifen. Eur J Cancer 2002; 38 Suppl 6:S49-51.
Nov 1, 2002Anastrozole versus progestins/tamoxifen
Nov 1, 2002Eur J Cancer 2002; 38 Suppl 6:S49-51
Thürlimann Beat